Faced with the global threat posed by the new coronavirus, several hundred international research teams have embarked on the quest for a vaccine. A colossal task, but one which is evolving much faster than twenty years ago during the SARS, explains Christiane Gerke, director of vaccine programs at the Pasteur Institute.
LE FIGARO. - How is the development of a vaccine at the Institut Pasteur going?
Christiane GERKE. - In the context of an epidemic, it is important to use a process that has already been tested in humans and has thus demonstrated its safety. We are currently working on three different techniques. The first is to use the measles vaccine as a carrier; it can be modified to protect against other pathogens than measles. We are also working with another transporter: a virus from the same family as HIV which has been modified to be harmless; this technology has already
This article is for subscribers only. You still have 72% to discover.
Subscribe: € 1 for 2 months
cancellable at any time
Enter your emailAlready subscribed? Login